Evidence map›Paper›PMID 36936689›Full record

ArticleFrontiers in cell and developmental biology2023

Patient-derived podocyte spheroids reveal new insights into the etiopathogenesis of Alport syndrome.

Ricardo Romero-Guevara, Orthodoxia Nicolaou, Benedetta Petracca, Sadr Shaheed, Christopher Sutton, Eleni Frangou, Marina Afami, Kyriacos Kyriacou, Adonis Ioannides, Christodoulos Xinaris

Open access · goldFull text read
In one paragraph

Article in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Ricardo Romero-GuevaraDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.
Orthodoxia NicolaouDepartment of Cancer Genetics, Therapeutics, and Ultrastructural Pathology, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Benedetta PetraccaLaboratory of Organ Regeneration, Department of Molecular Medicine, Institute of Pharmacological Research "Mario Negri", Bergamo, Italy.
Sadr ShaheedNuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
Christopher SuttonSchool of Chemistry and Bioscience, University of Bradford, Bradford, United Kingdom.
Eleni FrangouDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.
Marina AfamiDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.
Kyriacos KyriacouDepartment of Cancer Genetics, Therapeutics, and Ultrastructural Pathology, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Adonis IoannidesDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.
Christodoulos XinarisDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.
University of Cyprus · CYUniversity of Nicosia · CYCancer Genetics (United States) · USCyprus Institute of Neurology and Genetics · CYMario Negri Institute for Pharmacological Research · ITUniversity of Bradford · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alport syndrome (AS) is a rare disease characterized by defective glomerular basement membranes, caused by mutations in COL4A3, COL4A4, and COL4A5, which synthesize collagen type IV. Patients present with progressive proteinuria, hematuria and podocyte loss. There is currently no cure for Alport syndrome, and this is mainly due to its complex and variable pathogenesis, as well as the lack of models that can faithfully mimic the human phenotype. Here we have developed a novel human culture model of Alport syndrome and used it to study the effects of different mutations on podocyte development and biology. First, we established a differentiation protocol that allowed us to generate podocyte spheroids from patient-derived human induced pluripotent stem cells (hiPSCs). We have then carried out discovery proteomics and demonstrated that a total of 178 proteins were differentially expressed between Alport (AS1 and AS3) and control (LT) podocytes. GO analysis indicated alterations in several metabolic pathways, such as oxidative phosphorylation, RNA maturation, chromatin condensation, and proliferation. Although functional assays showed no changes in lactate production and mitochondrial potential compared to healthy controls, immunofluorescence and electron microscopy analysis showed key morphological changes related to the phenotypical maturation of Alport podocytes. Moreover, the studied mutations led to persistent proliferation, increased reactive oxygen species (ROS) production and the concomitant expression of peroxisome proliferator-activated receptors α and γ (PPARα and PPARγ) in podocytes. These data on patient-derived podocytes provide evidence that collagen mutations, in addition to playing a central role in the defective development of the glomerular filtration barrier, cause significant alterations in podocyte development and metabolism very early in development, even before the formation of the filtering apparatus. In conclusion, our study provides a new methodological platform for the differentiation of podocytes and to study human podocytopathies in a personalized manner, and reveals new insights into the etiopathogenesis and pathobiology of Alport syndrome.

Indexed as

Alport syndromedisease modelinginduced pluripotent stem cellspodocytesspheroids

Identifiers

PMID36936689
PMCPMC10018139
OpenAlexW4322773864

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read68
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.